ArticleClinical sarcoma research2015
Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.
Article in Clinical sarcoma research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 53 citations in OpenAlex.
- Epithelioid Hemangioendothelioma With a Novel Chromosomal Deletion and an Aggressive Clinical Course: A Case Report and Literature Review.Case reports in oncological medicine · 2026Article
- Disseminated hepatic epithelioid hemangioendothelioma with multiorgan metastases achieving long-term stability with Pazopanib: a case report.Frontiers in oncology · 2026Article
- The Diagnostic Dilemma of Incidentally Detected Pulmonary Nodules: A Fatal Case of Pulmonary Epithelioid Hemangioendothelioma.Respirology case reports · 2025Article
- Epithelioid Hemangioendothelioma: Treatment Landscape and Innovations for an Ultra-Rare Sarcoma.Current treatment options in oncology · 2025Review
- Case Report: A case of epithelioid hemangioendothelioma of the right femoral artery misdiagnosed as arterial occlusion.Frontiers in surgery · 2025Article
- The challenges of hepatic epithelioid hemangioendothelioma: the diagnosis and current treatments of a problematic tumor.Orphanet journal of rare diseases · 2024Review
- Article
- Irreversible Electroporation as a Valid Treatment Option for Hepatic Epithelioid Hemangioendothelioma: An International Multicenter Experience.Cardiovascular and interventional radiology · 2024Article
- Article
- Dual immunotherapy alternating with anti-PD-1 antibody plus liposomal doxorubicin show good efficacy in prostate epithelioid hemangioendothelioma: a case report.Frontiers in immunology · 2024Article
- Comprehensive evaluation of clinical outcomes in hepatic epithelioid hemangioendothelioma subsets: insights from SEER Database and departmental cohort analysis.Frontiers in immunology · 2024Article
- Primary pulmonary epithelioid hemangioendothelioma.BMJ case reports · 2023Article
- Hepatic epithelioid hemangioendothelioma-a single-institution experience with 51 cases.Frontiers in oncology · 2023Article
- Management and outcomes of advanced hemangioendothelioma at a medical oncology clinic in an Indian tertiary care center.Future science OA · 2022Article
- Case report: Successful treatment with the combined therapy of interferon-alpha 2b and anlotinib in a patient with advanced hepatic epithelioid hemangioendothelioma.Frontiers in medicine · 2022Article
- Sirolimus combined with interferon-alpha 2b therapy for giant hepatic epithelioid hemangioendothelioma: a case report.Frontiers in oncology · 2022Article
- Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature.Cancer medicine · 2021Review
- Hepatic epithelioid hemangioendothelioma: Update on diagnosis and therapy.World journal of clinical cases · 2020Review
- [Research Progress of Pulmonary Epithelioid Hemangioendothelioma].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2019Review
- Case report: A rare presentation of high risk epithelioid hemangioendothelioma on leg treated with surgical excision.International journal of surgery case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledEpithelioid hemangioendothelioma is a rare connective tissue tumor of vascular origin. It is most commonly found in young to middle aged women, and its clinical behavior is remakably variable from an indolent metastatic tumor to an aggressive rapidly growing neoplasm. Most tumors are diagnosed in an advanced unresectable phase and when clinically aggressive, require systemic cytotoxic treatment of sarcoma. Then, the 5-year survival rate after chemotherapy does not exceed 30%. Antiangiogenics are active in selected sarcoma subtypes: pazopanib, the only anti angiogenic registered agent for sarcoma provides a median PFS of 4.5 months only in the pivotal study. Their activity in EHE has been reported but long term outcome of these patients remain unreported. We report a case of a female patient with HEH who was treated with pazopanib for almost 8 years. Pazopanib therapy resulted in clinical improvement of symptoms and durable stabilization of liver tumors and lung lesions.
conclusionPazopanib is a promising therapeutic option in patients with HEH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.